These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. Mielcarek M; Burroughs L; Leisenring W; Diaconescu R; Martin PJ; Sandmaier BM; Maloney DG; Maris MB; Chauncey TR; Shizuru JA; Blume KG; Hegenbart U; Niederwieser D; Forman S; Bruno B; Woolfrey A; Storb R Br J Haematol; 2005 May; 129(3):381-91. PubMed ID: 15842663 [TBL] [Abstract][Full Text] [Related]
11. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283 [TBL] [Abstract][Full Text] [Related]
12. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Eppinger T; Ehninger G; Steinert M; Niethammer D; Dopfer R Transplantation; 1990 Nov; 50(5):807-11. PubMed ID: 2238056 [TBL] [Abstract][Full Text] [Related]
15. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402 [TBL] [Abstract][Full Text] [Related]
16. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris. Matsushita T; Hasegawa M; Shirasaki F; Fujimoto M; Yamazaki H; Sato S; Takehara K Dermatology; 2008; 216(1):64-7. PubMed ID: 18032902 [TBL] [Abstract][Full Text] [Related]
17. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768 [TBL] [Abstract][Full Text] [Related]
18. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related]